GlobeNewswire

ProMIS Neurosciences Completes US$7M (CDN$8.75M) Financing with Distinguished Group of Boston Based Investors

Share

TORONTO and CAMBRIDGE, Mass., March 22, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, is pleased to announce today the completion of an US$7M (CDN$8.75M) private placement of convertible unsecured debentures (the "Debentures").

The investors include Mike Gordon of Fenway Sports Group, the Kraft Group, Henry McCance, co-founder of the Cure Alzheimer’s Fund, and Jeremy Sclar of WS Development Group. “After conducting diligence with a number of experts in the field, we are impressed with the tremendous potential of ProMIS Neurosciences and its unique platform of drug candidates to have a profound impact in the fight against Alzheimer's and other neurodegenerative diseases.  Our group is pleased to provide funding for the next phase of the company's exciting future”, stated Mike Gordon of Fenway Sports Group.

“We are honored to have the support of such a distinguished group of investors, all of whom are accomplished leaders in the business and life sciences arenas,” said Gene Williams, ProMIS Executive Chairman.

Debenture Terms

The Debentures are convertible into ProMIS common shares at the option of the holder at a conversion price of US$0.10 per share and accrue interest at 1% per annum, which is payable annually. At the company’s election, accrued interest may be paid in cash or common shares (such number of shares determined by dividing the interest due by the 5-day volume-weighted average trading price or “VWAP” of the common shares).

The Debenture mature on March 22, 2026. Prior to the maturity date, the Company may force conversion of the Debentures at the conversion price upon raising US$50M in equity and/or debt cumulatively. On the maturity date, the Company may redeem the outstanding principal amount of the Debentures in either cash or common shares (at the then 5-day VWAP less a 10% discount) or a combination thereof at its election. Amounts redeemed in common shares on the Maturity Date will be subject to TSX acceptance.

The investors were granted a right to participate, on a pro rata basis, in subsequent company offerings of equity securities for cash consideration pursuant to a public offering or a private placement.

The Debentures and any common shares issued on conversion are subject to a four-month hold period that expires on July 22, 2021. Net proceeds will be used for working capital and general corporate purposes.

ProMIS plans to accelerate progress toward a number of top priorities, including:

  • Advancing the PMN310 monoclonal antibody, our potential “best in class” next generation Alzheimer’s treatment, into clinical testing;
  • Enhancing our partnering prospects for programs under active discussion by allowing us to invest in additional validation data;
  • Expanding our portfolio of products and intellectual property into new target areas, using our proprietary discovery platform;
  • Advancing our partnered diagnostic programs;
  • Achieving NASDAQ listing;
  • Expanding our Board of Directors; and
  • Expanding our management team, capitalizing on the talent pool in Boston, to support a growing and ambitious scope of activity.

Retirement of our CEO

Finally, a note of great appreciation for our CEO, Dr. Elliot Goldstein. Elliot, who just turned 70, has announced his intention to retire from a full time role by the end of 2021. Even though Elliot is irreplaceable, ProMIS has initiated a search for a new CEO to help us achieve our potential. “Elliot has been a close friend and valued business partner for decades,” said Gene Williams, “without his significant contributions, we would not have been able to take ProMIS from just a great science idea to a company with a growing portfolio of therapies that have the potential to be life-altering for patients. On behalf of the entire ProMIS community, and patients who in the future may benefit from our therapies, I offer Elliot our sincere thanks and gratitude”.

“ProMIS Neurosciences was launched six years ago based on a world class scientific platform from our CSO and scientific founder, Dr. Neil Cashman. Playing a key role in this endeavor has been one of the most challenging yet rewarding experiences of my 40 odd years in pharmaceutical drug development. I am delighted for this exciting new phase of the Company”, stated Dr. Elliot Goldstein, ProMIS CEO.

About ProMIS Neurosciences

ProMIS Neurosciences, Inc. is a development stage biotechnology company whose unique core technology is the ability to rationally predict the site and shape (conformation) of novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of proteins. In neurodegenerative diseases, such as Alzheimer’s, ALS and Parkinson’s disease, the DSEs are misfolded regions on toxic forms of otherwise normal proteins. ProMIS is headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on the Toronto Stock Exchange under the symbol PMN, and on the OTCQB Venture Market under the symbol ARFXF.

Visit us at www.promisneurosciences.com, follow us on Twitter and LinkedIn.

For Investor Relations please contact:
Alpine Equity Advisors
Nicholas Rigopulos, President
nick@alpineequityadv.com
Tel. 617 901-0785

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release contains certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.



About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

GOGL – Notice of Annual General Meeting 202120.4.2021 22:14:11 CEST | Press release

Golden Ocean Group Limited (the “Company”) announces that its 2021 Annual General Meeting will be held on May 26, 2021. A copy of the Notice of Annual General Meeting and associated information including the Company`s Consolidated Financial Statements on Form 20-F for 2020 can be found on our website at www.goldenocean.bm and in the links below. April 20, 2021 The Board of Directors Golden Ocean Group Limited Hamilton, Bermuda This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act Attachments GOGL - 2020 Form 20-FGOGL - Notice of Annual General Meeting 2021

RAPALA VMC CORPORATION ISSUES POSITIVE PROFIT WARNING AND UPGRADES ITS OUTLOOK FOR 2021: EXPECTS COMPARABLE OPERATING PROFIT TO INCREASE SIGNIFICANTLY FROM PRIOR YEAR20.4.2021 20:10:00 CEST | Press release

Rapala VMC Corporation Stock Exchange Release April 20, 2021 at 9:10 p.m. RAPALA VMC CORPORATION ISSUES POSITIVE PROFIT WARNING AND UPGRADES ITS OUTLOOK FOR 2021: EXPECTS COMPARABLE OPERATING PROFIT TO INCREASE SIGNIFICANTLY FROM PRIOR YEAR Rapala VMC Corporation’s outlook for 2021 has improved as a result of stronger than anticipated financial performance during the first three months of the year as well as upgraded positive business outlook for the remaining part of the year. The Group now expects full year 2021 comparable operating profit to increase significantly from the previous year. Key drivers behind the upgraded outlook are exceptionally strong winter sales, strong continued demand for fishing gear as it remains a popular COVID-safe activity globally as well as faster than expected strategy implementation. Uncertainties however remain for the rest of the year and the COVID-19 pandemic continues to pose some risks for the full-year performance. The pandemic can impact the oper

Korrigering till kallelse till Nexstim Abp:s bolagsstämma20.4.2021 20:00:00 CEST | Pressemelding

Företagsmeddelande,Helsingfors, 20.4.2021 kl.21.00 (EEST) Korrigering till kallelse till Nexstim Abp:s bolagsstämma Aktieägarna i bolaget har med en stämmokallelse av 15 april 2021 kallats till Nexstim Abp:s (NXTMH:HEX, NXTMS:STO) (”Nexstim” eller ”bolaget”) bolagsstämma som hålls 11 maj 2021 klockan 12.00 (EEST). Stämmokallelsen innehåller ett skrivfel enligt vilket den överföring av aktier till de mottagande aktieägarna som krävs för den slutliga ändringen av antalet aktier (efter minskningen) utförs och antecknas på värdeandelskontona troligen senast 17 maj i Sverige och 19 maj i Finland. Oaktat det ovannämnda utförs och antecknas överföringen på värdeandelskontona troligen senast 17 maj i Finland och 19 maj i Sverige. Punkt A.15. i kallelsen till extra bolagsstämman har således ändrats som följer (ändringarna i fet stil): Den överföring av aktier till de mottagande aktieägarna som krävs för den slutliga ändringen av antalet aktier (efter minskningen) utförs och antecknas på värdean

Correction to the Invitation to the Annual General Meeting of Nexstim Plc20.4.2021 20:00:00 CEST | Press release

Company announcement, Helsinki, 20.4.2021 at 9:00 pm (EEST) Correction to the Invitation to the Annual General Meeting of Nexstim Plc In accordance with the invitation to the Annual General Meeting of Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") dated 15 April 2021, the shareholders of the Company have been invited to the Annual General Meeting to be held on 11 May 2021 commencing at 12.00 (EEST). The invitation to the meeting of 15 April 2021 includes a writing error stating that transfers of shares from the Company to the Receiving Shareholders required for the final adjustments of their number of shares (after reduction) are expected to take place and be recorded in book-entry accounts at the latest on 17th May 2021 in Sweden and 19th May 2021 in Finland. Notwithstanding the above-mentioned, the transfers of shares are expected to take place and be recorded in book-entry accounts at the latest on 17th May 2021 in Finland and 19th May 2021 in Sweden. Consequently, it w

MSAB publicerar årsredovisning för 202020.4.2021 20:00:00 CEST | Pressemelding

MSABs årsredovisning för 2020 finns nu tillgänglig på bolagets hemsida, www.msab.com/investerare/finansiella-rapporter/, samt bilagt detta pressmeddelande. Tryckt version kommer att finnas tillgänglig inom kort och kan beställas hos bolaget per telefon + 46 (0) 8 739 02 70 eller per e-post info@msab.com. I moderbolagets resultaträkning har en utdelning erhållits från ett av bolagets utländska dotterbolag om 5.5 MSEK, vilket ej var inkluderat i bolagets bokslutskommuniké. Frågor ställs till: Verkställande direktör Joel Bollö, tel. 08-739 02 70, e-mail: joel.bollo@msab.com Denna information är sådan som MSAB, 556244-3050, är skyldigt att offentliggöra enligt lagen (2007:528) om värdepappersmarknaden. Informationen lämnades, genom ovanstående kontaktpersons försorg, för offentliggörande den 20 april 2021 klockan 20:00 CEST. Om MSAB MSAB är världsledande inom kriminalteknik för att utvinna och analysera data i beslagtagna mobila enheter. Företaget utvecklar högkvalitativ och lättanvänd mju

Flex LNG - AGM Notice20.4.2021 20:00:00 CEST | Press release

Flex LNG Ltd. (the "Company") announces that its 2021 Annual General Meeting will be held on May 26, 2021. A copy of the Notice of Annual General Meeting and associated information including the Company’s Annual Report on Form 20-F can be found in the links below and on our website at www.flexlng.com. April 20, 2021 The Board of Directors Flex LNG Limited Hamilton, Bermuda This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act or the Continuing Obligations of Oslo Børs. Attachments FLEX LNG - 20F 20202021 AGM Notice _FLEX (signed)

Banque Profil de Gestion SA : Assemblée Générale du 20 avril 202120.4.2021 18:04:22 CEST | Press release

Communiqué de presse Banque Profil de Gestion SA : Assemblée Générale du 20 avril 2021 Genève, le 20 avril 2021 – Lors de l’Assemblée Générale Ordinaire de la Banque Profil de Gestion SA (SIX Swiss Exchange : BPDG) qui s’est tenue aujourd’hui à Genève, 64.02% des actionnaires étaient représentés. Les actionnaires ont pris les décisions suivantes : Le rapport annuel et les comptes au 31 décembre 2020 ont été approuvés ;La pleine décharge a été donnée aux administrateurs de BPDG pour leur gestion durant l’exercice 2020 ;La couverture de la perte statutaire de CHF 2'336'667 avec la réserve légale issue du bénéfice a été approuvée ;Le versement d’un dividende de CHF 8'000'000 prélevé sur les réserves, soit un montant approximatif de CHF 0.5544 par action a été approuvé ;Madame Geneviève Berclaz, Monsieur Mario Aragnetti Bellardi, Monsieur Fabio Candeli, Monsieur Fulvio Pelli et Monsieur Fréderic Binder ont été réélus individuellement en qualité d’administrateur pour une durée de fonction d